Nucleic acids encoding B7-2 fusion proteins

Details Nucleic acids encoding B7-2 fusion proteins Nucleic acids encoding B7-2 fusion proteins

2003-05-02

2008-12-02

Gambel, Phillip (Department: 1644)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S023100

Reexamination Certificate

active

07459544

ABSTRACT:
Nucleic acids encoding novel CTLA4/CD28 ligands which costimulate T cell activation are disclosed. In one embodiment, the nucleic acid has a sequence which encodes a B lymphocyte antigen, B7-2. Preferably, the nucleic acid is a DNA molecule comprising at least a portion of a nucleotide sequence shown in FIG.8, SEQ ID NO:1 or FIG.14, SEQ ID NO:23. The nucleic acid sequences of the invention can be integrated into various expression vectors, which in turn direct the synthesis of the corresponding proteins or peptides in a variety of hosts, particularly eukaryotic cells, such as mammalian and insect cell culture. Also disclosed are host cells transformed to produce proteins or peptides encoded by the nucleic acid sequences of the invention and isolated proteins and peptides which comprise at least a portion of a novel B lymphocyte antigen. Proteins and peptides described herein can be administered to subjects to enhance or suppress T cell-mediated immune responses.

REFERENCES:
patent: 5116964 (1992-05-01), Capon et al.
patent: 5434131 (1995-07-01), Linsley
patent: 5434141 (1995-07-01), Schafer et al.
patent: 5580756 (1996-12-01), Linsley et al.
patent: 5747034 (1998-05-01), de Boer et al.
patent: 5770197 (1998-06-01), Linsley et al.
patent: 5786456 (1998-07-01), Ledbetter et al.
patent: 5869050 (1999-02-01), de Boer et al.
patent: 5942607 (1999-08-01), Freeman et al.
patent: 6071716 (2000-06-01), Freeman et al.
patent: 6090914 (2000-07-01), Linsley et al.
patent: 6130316 (2000-10-01), Freeman et al.
patent: WO-92/00092 (1992-01-01), None
patent: WO-93/00431 (1993-01-01), None
patent: WO-94/12520 (1994-06-01), None
patent: WO-95/03408 (1995-02-01), None
patent: WO-95/05464 (1995-02-01), None
patent: WO-95/06738 (1995-03-01), None
Riley et al., Blood, 105: 13-21, 2005.
Coyle et al., Nature Immunology 2: 203-209, 2001.
Attwood, Science 290: 471-473, 2000.
Skolnick et al., Trends in Biotech. 18: 34 39, 2000.
Metzier et al., Nature Structural Biol. 4: 527-531, 1997.
Perrin et al. J. Neuroimmunol. 65:31-39 (1996).
Blaear et al. J. Immunol. 157:3250-3254 (1996).
Yi-Qun et al. International Immunology 8:37-44 (1996).
Debets et al. Immunology Today 15:455-458(1994).
Skolnick et al. Trends In Biotechnology 18:34-39 (2000).
Lederman et al. Molecular Immunology 28:1171-1181 (1991).
Kahan Current Opinion in Immunology 4:553-560(1992).
Edgington Biotechnology 10:383-389 (1992).
Ngo et al. in The Protein Folding Problem and Tertiary Structure Prediction. Menz et al. (eds.) Birkhawer Boyton 1994. pp. 433, 492-495.
Sturmhoefer et al. Cancer Research 59:4964-4972 (1999).
Azuma, M. et al., “B70 antigen is a second ligand for CTLA-4 and CD28,” Nature 366:76-79 (1993).
Azuma, M. et al., “Involvement of CD28 in MHC-unrestricted cytotoxicity mediated by a human natural killer leukemia cell line,” J. Immunol. 149(4):1115-1123 (1992).
Baskar, S. et al. (1993) “Constitutive Expression of B7 Restores Immunogenicity of Tumor Cells Expressing Truncated Major Histocompatibility Complex Class II Molecules” Proc. Natl. Acad. Sci. USA 90:5687-5690.
Chen, L. et al. (1992) “Costimulation of Antitumor Immunity by the B7 Counterreceptor For the T Lymphocyte Molecules CD2B and CTLA-4” Cell 71:1093-1102.
Classon et al., “The hinge region of the CD8 alpha chain: structure, antigenicity, and utility in expression of immunoglobulin superfamily domains,” Int. Immunol. 4(2):215-225 (1992).
Clements, V.K. et al. (1992) “Invariant Chain Alters The Malignant Phenotype of MHC Class II.sup.+ Tumor Cells” J. of Immunology 149:2391-2396.
Cole, G.A. et al. (1991) “Rejection of Allogeneic Tumor Is Not Determined by Host Responses to MHC Class I Molecules and is Mediated By CD4.sup.- CD8+ T Lymphocytes That Are Not Lytic for the Tumor” Cellular Immunology 134:480-490.
Fearon, E.R. et al. (1990) “Interleukin-2 Production By Tumor Cells Bypasses T Helper Function in the Generation of An Antitumor Response” Cell 60:397-403.
Freedman, A. S. et al. (1987) “B7, A B Cell-Restricted Antigen That Identifies Preactivated B Cells” Journal of Immunology 139(10); 3260-3267.
Freeman et al., “Structure, Expression, and T Cell Costimulatory Activity of the Murine Homologue of the Human B Lymphocyte Activation Antigen B7” Journal Experimental Medicine, vol. 174, pp. 625-631, (1991).
Freeman, G., et al., “Cloning of B7-2; A CTLA-4 Counter-Receptor that Costimulates Human T Cell Proliferation,” Science, vol. 262, 909-911 (1993).
Galvin, F. et al. (1992) “Murine B7 Antigen Provides A Sufficient Costimulatory Signal For Antigen-Specific and MHC-Restricted T Cell Activation” J. Immunology 149:3802-3808.
Gimmi et al., “B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2” Proceedings of the National Academy of Science, vol. 88, pp. 6575-6579, (1991).
Gimmi, C., et al., “Human T-cell Clonal Anergy is Induced by Antigen Presentation in the Absence of B7 Costimulation,” Proc. Natl. Acad. Sci. USA, vol. 90, 6586-6590 (1993).
Guo, Y. et al. (1995) “Mutational Analysis and an Alternatively Spliced Product of B7 Defines Its CD28/CTLA4-binding Site on Immunoglobulin C-like Domain” J. Exp. Med., 181:1345-1355.
Harding, F. and Allison, J., “CD28-B7 Interactions Allow the Induction of CD8.sup.+ Cytotoxic T Lymphocytes in the Absence of Exogeneous Help,” J. Exp. Med., vol. 177, 1791-1796 (1993).
Harding, F., et al., “CD28-medicated Signalling Co-stimulates Murine T Cells and Prevents Induction of Anergy in T-cell Clones,” Nature, vol. 356, 607-609 (1992).
Hollenbaugh and A. Aruffo (1992) “Construction of Immunoglobulin Fusion Proteins” Immunology Suppl. 4, Unit 10.19: 1-11.
Inobe, M. et al. (1994) “Identification of an Alternatively Spliced Form of the Murine Homologue of B7”, Biochemical and Biophysical Research Communication 200(1):443-449.
James, R.F.L. “The effect of class II gene transfection on the tumourigenicity of the H-2K-negative mouse leukaemia cell line K36.16,” Immunology. Feb. 1991;72(2):213-8.
June, C.H. et al., “The B7 and CD28 receptor families,” Immunol. Today, Jul. 1994;15(7):321-31.
Lanier, L.L. et al., “CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL,” J. Immunol. Jan. 1, 1995;154(1):97-105.
Lenschow, D.J. et al., “Expression and functional significance of an additional ligand for CTLA-4,” Proc. Natl. Acad. Sci. U. S. A. Dec. 1, 1993;90(23):11054-8.
Lenschow, D.J. et al., “Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg,” Science, Aug. 7, 1992;257(5071):789-92.
Linsley, P.S. et al., “Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation Molecule,” Science, Aug. 7, 1992;257(5071):792-5.
Lin, H. et al., “Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4lg plus donor-specific transfusion,” J. Exp. Med., Nov. 1, 1995;178(5):1801-6.
Nabavi, N. et al., “Signalling through the MHC class II cytoplasmic domain is required for antigen presentation and induces B7 expression,” Nature Nov. 19, 1992;360(6401):266-8.
Ostrand-Rosenberg, S. et al., “Costimulation through murine B7 molecule restores immunogenicity of autologous tumor cells expressing truncated MHC class II molecules,” J. Cell Biochem. Suppl. (Abstract HZ 228) (1993) p. 71.
Ostrand-Rosenberg, S. et al., “Abrogation of tumorigenicity by MHC class II antigen expression requires the cytoplasmic domain of the class II molecule,” J. Immunol., Oct. 1, 1991;147(7):2419-22.
Ostrand-Rosenberg, S. et al., “Rejection of mouse sarcoma cells after transfection of MHC class II genes,” J. Immunol., May 15, 1990;144(10):4068-71.
Reiser, H. et al., &#

Affiliated with

Also associated with

Rating

Nucleic acids encoding B7-2 fusion proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nucleic acids encoding B7-2 fusion proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acids encoding B7-2 fusion proteins will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4040137